



August 8, 2016

## **Aldeyra Therapeutics Schedules Conference Call to Present Results of a Randomized, Double-Blind, Vehicle-Controlled Clinical Trial in Sjogren-Larsson Syndrome**

LEXINGTON, MA -- (Marketwired) -- 08/08/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that, on Tuesday, August 9, 2016, prior to the market open, it will report the results of a randomized, parallel-group, double-blind, vehicle-controlled, multi-center clinical trial of topical dermatologic NS2, a novel aldehyde trap, in patients with Sjögren-Larsson Syndrome.

Aldeyra will hold a conference call with slides on Tuesday, August 9, 2016 at 8:00 a.m. EDT to discuss the results of the clinical trial. The dial-in numbers are 1-888-296-4215 for domestic callers and 1-719-325-2480 for international callers. The conference ID number for both is 4144869. A live webcast of the conference call and accompanying slides will be available on the investor relations page of the Aldeyra Therapeutics corporate website at [www.aldeyra.com](http://www.aldeyra.com).

After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year. In addition, a telephonic replay of the call will be available until August 8, 2017. The replay dial-in numbers are 1-888-203-1112 for domestic callers and 1-719-457-0820 for international callers. Please use event passcode 4144869.

### ***About Aldeyra Therapeutics***

Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, NS2, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. NS2 has not been approved for sale in the U.S. or elsewhere.

### ***About Sjögren-Larsson Syndrome***

Sjögren-Larsson Syndrome is a rare inborn error of aldehyde metabolism caused by mutations in fatty acid aldehyde dehydrogenase, leading to elevated toxic fatty aldehyde levels that are thought to contribute to severe ichthyosis (scaly, thickened, dry skin), neurological disorders, and retinal disease. There is no therapy for SLS that has been approved by the U.S. Food and Drug Administration.

### ***About NS2***

NS2 is an aldehyde-binding small molecule based on an innovative platform technology focused on trapping aldehydes, which are toxic and pro-inflammatory mediators of numerous diseases. By decreasing aldehyde load, NS2 may mitigate excessive inflammation and address diseases where aldehyde metabolism is impaired, including certain inborn errors of metabolism.

#### **Corporate Contact:**

Stephen Tulipano  
Aldeyra Therapeutics, Inc.  
Tel: +1 781-761-4904 ext. 205  
[Email Contact](#)

#### **Investor Contact:**

Chris Brinzey  
Westwicke Partners  
Tel: 339-970-2843  
[Email Contact](#)

#### **Media Contact:**

Cammy Duong  
MacDougall Biomedical Communications  
781-591-3443  
[Email Contact](#)

Source: Aldeyra Therapeutics

News Provided by Acquire Media